FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976501464> ?p ?o ?g. }

• W1976501464 abstract "To systematically review the effectiveness and cost-effectiveness of palivizumab for the prevention of respiratory syncytial virus (RSV) in children and examine prognostic factors to determine whether subgroups can be identified with important differences in cost-effectiveness.Bibliographic databases were searched from inception to March 2007 for literature on the effectiveness and cost-effectiveness of prophylaxis with palivizumab.The literature was systematically reviewed and current economic evaluations were analysed to identify which parameters were driving the different cost-effectiveness estimates. A probabilistic decision-analytical model was built to assess the cost-effectiveness of prophylaxis with palivizumab for children at risk of RSV infection and the parameters populated with the best estimates thought most applicable to the UK. We also constructed a new model, the Birmingham Economic Evaluation (BrumEE). Cost-effectiveness analyses were undertaken from both NHS and societal perspectives.Two randomised controlled trials (RCTs) were identified. Prophylaxis with palivizumab for preterm infants without chronic lung disease (CLD) or children with CLD resulted in a 55% reduction in RSV hospital admission: 4.8% (48/1002) in the palivizumab group and 10.6% (53/500) in the no prophylaxis group (p = 0.0004). Prophylaxis with palivizumab was associated with a 45% reduction in hospitalisation rate RSV among children with coronary heart disease (CHD). Hospitalisation rates for RSV were 5.3% (34/639) in the palivizumab group and 9.7% (63/648) in the no prophylaxis group (p = 0.003). Of existing economic evaluations, 3 systematic reviews and 18 primary studies were identified. All the systematic reviews concluded that the potential costs of palivizumab were far in excess of any potential savings achieved by decreasing hospital admission rates, and that the use of palivizumab was unlikely to be cost-effective in all children for whom it is recommended, but that its continued use for particularly high-risk children may be justified. The incremental cost-effectiveness ratios (ICERs) of the primary studies varied 17-fold for life-years gained (LYG), from 25,800 pounds/LYG to 404,900 pounds/LYG, and several hundred-fold for quality-adjusted life-years (QALYs), from 3200 pounds/QALY to 1,489,700 pounds/QALY for preterm infants without CLD or children with CLD. For children with CHD, the ICER varied from 5300 pounds/LYG to 7900 pounds/LYG and from 7500 pounds/QALY to 68,700 pounds/QALY. An analysis of what led to the discrepant ICERs showed that the assumed mortality rate for RSV infection was the most important driver. The results of the BrumEE confirm that palivizumab does not reach conventional levels of cost-effectiveness in any of the licensed indications if used for all eligible children.Prophylaxis with palivizumab is clinically effective for the reducing the risk of serious lower respiratory tract infection caused by RSV infection and requiring hospitalisation in high-risk children, but if used unselectively in the licensed population, the ICER is double that considered to represent good value for money in the UK. The BrumEE shows that prophylaxis with palivizumab may be cost-effective (based on a threshold of 30,000 pounds/QALY) for children with CLD when the children have two or more additional risk factors. Future research should initially focus on reviewing systematically the major uncertainties for patient subgroups with CLD and CHD and then on primary research to address the important uncertainties that remain." @default.
• W1976501464 created "2016-06-24" @default.
• W1976501464 creator A5009998303 @default.
• W1976501464 creator A5024713442 @default.
• W1976501464 creator A5028984464 @default.
• W1976501464 creator A5066938458 @default.
• W1976501464 creator A5077246683 @default.
• W1976501464 date "2008-12-01" @default.
• W1976501464 modified "2023-10-10" @default.
• W1976501464 title "Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation" @default.
• W1976501464 cites W131464745 @default.
• W1976501464 cites W14052386 @default.
• W1976501464 cites W1488603340 @default.
• W1976501464 cites W1504523720 @default.
• W1976501464 cites W1507293869 @default.
• W1976501464 cites W1510386142 @default.
• W1976501464 cites W1521266957 @default.
• W1976501464 cites W1524506629 @default.
• W1976501464 cites W1541080151 @default.
• W1976501464 cites W1554745563 @default.
• W1976501464 cites W1559018917 @default.
• W1976501464 cites W1642866390 @default.
• W1976501464 cites W173554462 @default.
• W1976501464 cites W1861504425 @default.
• W1976501464 cites W1951007341 @default.
• W1976501464 cites W1966099212 @default.
• W1976501464 cites W1966444218 @default.
• W1976501464 cites W1966897685 @default.
• W1976501464 cites W1969006368 @default.
• W1976501464 cites W1970616811 @default.
• W1976501464 cites W1972203198 @default.
• W1976501464 cites W1973185874 @default.
• W1976501464 cites W1973885488 @default.
• W1976501464 cites W1974519240 @default.
• W1976501464 cites W1974618052 @default.
• W1976501464 cites W1979032749 @default.
• W1976501464 cites W1979156497 @default.
• W1976501464 cites W1981501248 @default.
• W1976501464 cites W1983914898 @default.
• W1976501464 cites W1984386330 @default.
• W1976501464 cites W1986348763 @default.
• W1976501464 cites W1988516867 @default.
• W1976501464 cites W1988676847 @default.
• W1976501464 cites W1990315067 @default.
• W1976501464 cites W1990777888 @default.
• W1976501464 cites W1991216993 @default.
• W1976501464 cites W1992254924 @default.
• W1976501464 cites W1993282245 @default.
• W1976501464 cites W1993553202 @default.
• W1976501464 cites W1994032445 @default.
• W1976501464 cites W1994149977 @default.
• W1976501464 cites W1994394357 @default.
• W1976501464 cites W1994616086 @default.
• W1976501464 cites W1995067043 @default.
• W1976501464 cites W1996151477 @default.
• W1976501464 cites W1996607042 @default.
• W1976501464 cites W1996784517 @default.
• W1976501464 cites W1998094270 @default.
• W1976501464 cites W2001409963 @default.
• W1976501464 cites W2001597243 @default.
• W1976501464 cites W2002600726 @default.
• W1976501464 cites W2002722261 @default.
• W1976501464 cites W2007476930 @default.
• W1976501464 cites W2009110528 @default.
• W1976501464 cites W2012202151 @default.
• W1976501464 cites W2013504325 @default.
• W1976501464 cites W2014939976 @default.
• W1976501464 cites W2014979672 @default.
• W1976501464 cites W2016383224 @default.
• W1976501464 cites W2018672014 @default.
• W1976501464 cites W2020628724 @default.
• W1976501464 cites W2022950741 @default.
• W1976501464 cites W2023865002 @default.
• W1976501464 cites W2023903184 @default.
• W1976501464 cites W2025489299 @default.
• W1976501464 cites W2027666532 @default.
• W1976501464 cites W2027904579 @default.
• W1976501464 cites W2028362308 @default.
• W1976501464 cites W2028479357 @default.
• W1976501464 cites W2029503764 @default.
• W1976501464 cites W2031130235 @default.
• W1976501464 cites W2033257301 @default.
• W1976501464 cites W2033875888 @default.
• W1976501464 cites W2035243389 @default.
• W1976501464 cites W2035247227 @default.
• W1976501464 cites W2036877259 @default.
• W1976501464 cites W2040560891 @default.
• W1976501464 cites W2041643208 @default.
• W1976501464 cites W2041934298 @default.
• W1976501464 cites W2042415429 @default.
• W1976501464 cites W2042887042 @default.
• W1976501464 cites W2043258977 @default.
• W1976501464 cites W2043557812 @default.
• W1976501464 cites W2044486890 @default.
• W1976501464 cites W2046119563 @default.
• W1976501464 cites W2049523070 @default.
• W1976501464 cites W2051007466 @default.
• W1976501464 cites W2054402147 @default.
• W1976501464 cites W2057472565 @default.
• W1976501464 cites W2058207519 @default.

• next